What is Tactile Systems's latest dividend and current dividend yield?

What guidance did Tactile Systems's management provide for the next earnings period?

What were the key takeaways from Tactile Systems's earnings call?

What does Tactile Systems do and what are its main business segments?

What is the revenue and EPS growth rate for Tactile Systems year over year?

What factors drove the changes in Tactile Systems's revenue and profit?

Did Tactile Systems beat or miss consensus estimates last quarter?

What were the key takeaways from Tactile Systems’s earnings call?

- **Revenue Momentum**: 2025 revenue +12% to $329.5M; Q4 +21% to $103.6M. 2026 guidance $357-365M (+8-11%).
- **Gross Margin Expansion**: Full year 75.9% (+190bps YoY). Q4 78.2% vs 75.2% prior.
- **Strategic Acquisition**: LymphaTech 3D scanning tech to enhance lymphedema assessment accuracy and accelerate therapy access.
- **Medicare Prior Auth**: Short-term headwind in 2026 but manageable with prior auth expertise; 2026 guidance reflects 1-2Q impact.
- **EBITDA Growth**: 2025 adjusted EBITDA $44.8M (+21% YoY). 2026 target $49-51M (13.8-14.0% margin).

**【CEO Summary Section】**
- **Revenue Growth**: Total 2025 revenue of $329.5 million, up 12% YoY. Q4 2025 revenue $103.6 million, +21% YoY. Lymphedema revenue +16% YoY to $89.5 million; airway clearance +66% YoY to $14.1 million.
- **Gross Margin Expansion**: Full year gross margin 75.9% (+190bps YoY). Q4 gross margin 78.2% vs 75.2% YoY prior.
- **Cash Position**: Ended 2025 with $83.4M cash, after repaying $26.3M term loan and $26.5M stock buybacks. 2026 revenue guidance $357-365M (+8-11% YoY).
- **LymphaTech Acquisition**: $10M upfront + $15M contingent for digital 3D scanning tech. Expands lymphedema solutions, improves patient assessment accuracy.
- **Strategic Priorities**: Improve access via AI-enabled order process; expand product line with Nimbl leadership in basic pumps; enhance patient engagement through Kylee app.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: GAAP net income $10.6M ($0.46 EPS) vs $9.7M ($0.40 EPS). Adjusted EBITDA $22M vs $16.2M YoY.
- **2026 Outlook**: GAAP gross margin 76%; operating expenses +8-10% YoY. Adjusted EBITDA $49-51M. Tax rate 28%; shares 22-23M.
- **Medicare Impact**: New prior auth for pneumatic devices effective April 2026. Short-term headwind but manageable with existing prior auth expertise.
- **Cash Flow**: 2025 operating cash flow $43M. Free cash flow after capex $35M.

**【Q&A Highlights】**
- **Prior Auth Balance**: Tailwinds from NCD interpretation offset by Medicare prior auth. 2026 guidance reflects 1-2Q short-term impact, then return to market growth.
- **LymphaTech Integration**: Immediate commercial availability; plans to integrate into sales process with 2026 pilots. Potential for new reimbursement codes.
- **EBITDA Leverage**: 2025 EBITDA margin 7.3% vs 5.5% YoY. 2026 target 13.8-14.0% with operating expense control and gross margin expansion.
- **Airway Clearance Growth**: 2025 +66% YoY; 2026 expects normalization but sustained momentum from DME partnerships and new AffloVest features.
- **R&D Pipeline**: Nimbl market leader in basic pumps; next-gen AffloVest with connectivity launching 2026. Advanced pump enhancements (smaller, lighter) in development.

Tactile Systems Technology, Inc. (TCMD) Q4 2025 Earnings Call Transcript

- **Revenue surge**: Q3 2025 total revenue $85.8M (+17% YoY), with airway clearance up 71% YoY and lymphedema +11% YoY.
- **Strategic wins**: 329 reps driving lymphedema recovery, AffloVest near market leader, and $25M share buyback.
- **Profit growth**: EBITDA +34% YoY to $14.4M, net income +59% YoY.
- **Future tailwinds**: NCD policy, next-gen AffloVest, and AI-driven order efficiency.
- **Risk mitigation**: Tariff impact reduced to $1M in 2025.

**【CEO Summary Section】**
- Total Q3 2025 revenue: $85.8 million (+17% YoY), driven by lymphedema ($72.4M, +11% YoY) and airway clearance ($13.4M, +71% YoY). Sequential growth: lymphedema +10%, airway clearance +3%.
- Lymphedema recovery: 329 reps (vs. 260 at end-Q1), 1:1 account manager/product specialist model, and CRM adoption boosting productivity. Medicare channel rebound (+130% YoY) offset by commercial/VA declines.
- Airway clearance momentum: AffloVest partnerships with top 10 DMEs, 5M+ bronchiectasis patients, and next-gen product (FDA review pending).
- Strategic priorities: AI in order ops, Nimbl market leadership, and care navigation pilots for patient engagement.
- Guidance update: Full-year 2025 revenue $317-321M (+8-10% YoY), EBITDA $38-39.5M.

**【CFO Financial Commentary】**
- Q3 2025 GAAP net income: $8.2M ($0.36 EPS), +59% YoY. Adjusted EBITDA: $14.4M (+34% YoY). Gross margin: 76% (vs. 75% YoY).
- Operating expenses: $54M (+13% YoY), driven by sales (+$3M) and tech investments. Free cash flow: $66M (no debt).
- 2025 outlook: Lymphedema +3-4%, airway clearance +52-55%. Tariff impact $1M (halved post-2025).

**【Q&A Key Highlights】**
- **AffloVest sustainability**: DME partnerships, market awareness, and product differentiation. Near #1 share vs. Baxter. 2025 growth +71% vs. 2024 +11%.
- **Lymphedema growth drivers**: 329 reps, CRM, and NCD tailwind (direct access to advanced pumps). Sequential productivity gains and 2026 market growth expectations.
- **Investments**: $25M share repurchase, AI/CRM, and care navigation. 2025 EBITDA +34% YoY.
- **Policy impact**: NCD allowing head/neck lymphedema patients to bypass basic pumps. 2026 policy changes expected.
- **Tariff mitigation**: 2025 impact $1M, post-2025 $0.5M annualized.

Tactile Systems Technology, Inc. (TCMD) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 up 7.8% to $78.9M, driven by 51.6% jump in airway clearance sales and 2% lymphedema growth.
- **Margin Expansion**: Gross margin +60bps to 74.5%, despite $7.7M adj. EBITDA (-15% YoY) due to investments.
- **Strategic Momentum**: Nimbl adoption outpaces market; AI tools pilot to automate 1,000+ daily faxes, cutting order processing time 50%.
- **Guidance Raise**: FY25 revenue $310-315M (+6-8% YoY), adj. EBITDA $33-35M, reflecting CRM stabilization and AffloVest share gains.
- **Reimbursement Breakthrough**: Medicare clarifications enable direct advanced pump access for head/neck lymphedema; commercial payers revising policies post clinical data.

**【CEO Summary Section】**
- Total revenue grew 7.8% YoY to $78.9 million, driven by 2% lymphedema revenue ($66 million) and 51.6% airway clearance revenue ($12.9 million). 
- Q2 gross margin improved 60bps to 74.5%, with adjusted EBITDA of $7.7 million (-15% YoY) due to strategic investments.
- Sales force expanded to 293 reps (+11% QoQ), targeting 300+ by year-end. Nimbl adoption outpaced market growth, while Flexitouch remains majority share.
- Strategic priorities: improving access via AI tools (e.g., order intake automation pilot), expanding treatment options (next-gen pump R&D), and enhancing patient value (Kylee engagement tool usage up 53k profiles, 1.1M check-ins).

**【CFO Financial Commentary】**
- FY25 guidance: $310-315M revenue (+6-8% YoY), 75% GAAP gross margin, $33-35M adj. EBITDA.
- Q2 financials: $3.2M net income (-25% YoY), $81.5M cash post $16.5M buyback. FY25 tariff impact reduced to $1-1.5M.
- Operating expenses +13% YoY to $54.7M, driven by tech investments and sales growth. FY25 opex expected +10-11% YoY.

**【Q&A Highlights】**
- **Guidance Adjustment**: Q2 beat ($5M) led to $1M midpoint raise, reflecting CRM stabilization and AI tool potential, but tempered by scaling risks.
- **Reimbursement Progress**: Medicare NCD clarifications enabling direct advanced pump access for head/neck lymphedema; commercial payers showing policy openness post clinical data presentations.
- **Market Share Dynamics**: Nimbl growing faster than market (10% CAGR), but lower ASPs limiting revenue growth. Lymphedema diagnosed patient penetration <10%, with 2M+ untreated.
- **Sales Productivity**: AI tools expected to reduce order processing time by 50%, reducing leakage and improving rep focus on clinician engagement.


Tactile Systems Technology, Inc. (TCMD) Q2 2025 Earnings Call Transcript

- **Revenue Mixed**: Q1 2025 revenue flat YoY ($61.3M), with airway clearance (+22%) offsetting lymphedema decline (-3%).
- **Margin Improvement**: Gross margin up 290bps to 74%, but EBITDA negative due to CRM and headcount investments.
- **Growth Drivers**: Nimbl adoption in Medicare (+6% YoY), AffloVest #2 in bronchiectasis, and 2025 guidance of $309-315M (+5-8% YoY).
- **Risks**: Tariffs could add $1M COGS, but 2026+ leverage expected from 300+ reps and CRM efficiency.
- **Key Metrics**: 50,000 Kylee users, 62% PEC demos, and 25% Nimbl orders via Parachute.

**【CEO Summary Section】**
- **Q1 2025 Revenue**: Total revenue of $61.3 million, up 0.3% YoY. Lymphedema revenue decreased 3% to $50.6 million, while airway clearance revenue surged 22% to $10.7 million.
- **Gross Margins**: Improved 290 basis points YoY to 74%, driven by lower manufacturing and warranty costs.
- **Strategic Challenges**: Q1 lymphedema underperformance due to sales headcount reduction (280 reps → 264 reps) and CRM implementation delays. Reps are now 80% proficient with the new Salesforce CRM.
- **Sales Growth Plan**: Targeting 300+ reps by end-2025, with Nimbl adoption outpacing market growth. AffloVest maintains #2 market share in bronchiectasis.
- **Strategic Priorities**: 
  1. **Access to Care**: CRM modernization, e-prescribing (Parachute) adoption, and Kylee patient engagement tool (50,000+ profiles).
  2. **Treatment Expansion**: Nimbl adoption in Medicare channels, Flexitouch for VA/commercial.
  3. **Patient Value**: Centralized Patient Services team, 62% in-home demos by PECs.

**【CFO Financial Commentary】**
- **Q1 Financials**: GAAP net loss of $3 million (-35% YoY), adjusted EBITDA loss of $0.3 million (vs. $1 million YoY). Operating expenses +8% YoY to $49.9 million due to tech investments.
- **Balance Sheet**: $83.6 million cash (down $10.7 million QoQ) after $10M stock buybacks. Full-year 2025 guidance: $309-315M revenue (+5-8% YoY), 4-5% lymphedema growth, 20-23% airway clearance growth.
- **Tariff Mitigation**: $1M COGS impact assumed, with reshoring and supplier absorption strategies in place.

**【Q&A Highlights】**
- **Revenue Guidance**: High end assumes faster CRM adoption and Parachute rollout; low end accounts for hiring delays. Q4 2025 expected to show mid-teens sequential growth.
- **Nimbl Performance**: 25% of lymphedema orders via Parachute, Medicare channel growth 6% YoY. Nimbl adoption driven by ease of use and CRM integration.
- **Leverage Outlook**: 2026+ operating expense leverage from 300+ reps and reduced tech spend. 2025 OpEx +9-11% YoY for sales and tech investments.
- **Tariff Risk**: <5% COGS impact, with mitigation strategies reducing exposure.


Tactile Systems Technology (TCMD)-5 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: FY2024 total revenue $293M (+6.8% YoY), Q4 $85.6M (+10.2% YoY). 2025 guidance: $316-322M (+8-10% YoY).
- **Margin Expansion**: Q4 gross margin 75.2% (+310 bps YoY). 2025 GAAP gross margin ~74%.
- **Strategic Priorities**: Nimbl lower extremity launch, Medicare NCD policy normalization, and 10%+ specialist headcount growth.
- **AffloVest Momentum**: 2025 DME contract expansion targeting 6-9% growth, 5 million undiagnosed bronchiectasis patients.
- **Head & Neck Opportunity**: 6-month study data analysis underway, 90% of 400k head/neck cancer patients have Lymphedema.

**【CEO Summary Section】**
- **Q4 and FY2024 Financial Highlights**: Total revenue of $293 million (+6.8% YoY), Q4 revenue $85.6 million (+10.2% YoY). Lymphedema sales grew 11% YoY in Q4, driven by Nimbl launch and CRM modernization. Airway Clearance (AffloVest) sales up 3.8% YoY.
- **Gross Margin Expansion**: Q4 gross margin improved 310 bps YoY to 75.2%, driven by lower manufacturing costs and better collections.
- **2025 Guidance**: Full year revenue $316-322 million (+8-10% YoY). Strategic priorities include improving access to care, expanding treatment options, and supporting long-term patient management.
- **Nimbl Expansion**: Lower extremity launch in Feb 2025, targeting 16 million patients with 94% less hosing than Entre Plus.
- **Sales Leadership Change**: Aaron Snodgrass promoted to SVP of Sales, focusing on streamlining field roles (Account Managers & Specialists) and PEC utilization (52% of demos in Q4).

**【CFO Financial Commentary】**
- **Q4 Financials**: GAAP net income $9.7 million (+18.3% YoY), Adjusted EBITDA $16.2 million (+5.5% YoY). Cash balance $94.4 million (+$33 million YoY).
- **2025 Outlook**: GAAP gross margin ~74%, operating expenses to grow mid-double digits due to sales investments. Adjusted EBITDA $35-37 million, reflecting strategic tech and headcount additions.
- **Balance Sheet Strength**: $94.4 million cash, no debt. Free cash flow generation supports reinvestment in growth initiatives.

**【Q&A Key Takeaways】**
- **2025 Growth Drivers**: Nimbl adoption, CRM efficiency, Medicare NCD policy normalization, and DME contract expansion for AffloVest.
- **EBITDA Guidance**: Flat to down due to $15 million+ investments in sales infrastructure and tech modernization.
- **Head & Neck Study**: 6-month data analysis underway, potential 2025 peer-reviewed publication. 90% of 400k head/neck cancer patients have Lymphedema, creating large addressable market.
- **Patient Leakage Mitigation**: PEC utilization (52% of demos in Q4) and Kylee app adoption to reduce order process friction.
- **Inorganic Growth Appetite**: Focused on strategic, accretive opportunities aligned with Lymphedema care pathway expansion.

Actual											-0.07	-0.72	0.12	0.61	-0.12	0.07	-0.082	-0.2787	-0.4216	-0.1438	0.0957	0.2917	-0.033	0.049	0.8533	0.3798	-0.0499	0.18	0.21	0.4	-0.13	0.14	0.36	0.46
Forecast											-0.0243	-0.2214	-0.06	0.2474	-0.154	0.01	0.12	-0.0026	-0.2775	-0.1167	-0.055	0.1433	-0.2385	-0.05	0.0275	0.2118	-0.0775	0.1446	0.1827	0.315	-0.08	0.1075	0.1679	0.4365
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-188.07%	-225.20%	+300.00%	+146.56%	+22.08%	+600.00%	-168.33%	-10619.23%	-51.93%	-23.22%	+274.00%	+103.56%	+86.16%	+198.00%	+3002.91%	+79.32%	+35.61%	+24.48%	+14.94%	+26.98%	-62.50%	+30.23%	+114.41%	+5.38%

TCMD

TCMD fundamentals

TCMD Q4 2025 Earnings

Earnings Call

You can ask Aime

TCMD

TCMD fundamentals

TCMD Q4 2025 Earnings

Earnings Call

TCMD Earnings Call Summary for Q4/20255:00 PM on Feb 17, 2026

TCMD Earnings Call Summary for Q3/20255:00 PM on Nov 3, 2025

TCMD Earnings Call Summary for Q2/20255:00 PM on Aug 4, 2025

TCMD Earnings Call Summary for Q1/20255:00 PM on May 5, 2025

TCMD Earnings Call Summary for Q4/20245:00 PM on Feb 18, 2025

You can ask Aime